A phase II trial of combination of CPT-11 and cisplatin for advanced non-small-cell lung cancer
1998

Combination of CPT-11 and Cisplatin for Lung Cancer

Sample size: 70 publication Evidence: moderate

Author Information

Author(s): N Masuda, M Fukuoka, A Fujita, Y Kurita, S Tsuchiya, K Nagao, S Negoro, H Nishikawa, N Katakami, K Nakagawa, H Niitani

Primary Institution: Osaka Prefectural Habikino Hospital

Hypothesis

The study aims to confirm the activity and toxicities of CPT-11 and cisplatin combination for previously untreated non-small-cell lung cancer (NSCLC).

Conclusion

The combination of CPT-11 and cisplatin is effective against non-small-cell lung cancer with acceptable toxicities.

Supporting Evidence

  • Thirty-three patients (52%) achieved an objective response, with one complete response (2%) and 32 partial responses (50%).
  • The median duration of response was 19 weeks and the overall median survival time was 44 weeks.
  • The 1-year survival rate was 33%.

Takeaway

Doctors tested a new medicine called CPT-11 with another medicine called cisplatin to help people with a type of lung cancer, and it worked pretty well.

Methodology

Seventy patients with stage IIIB or IV NSCLC received CPT-11 and cisplatin in a multi-institutional phase II study, with assessments made of response, survival, and toxicities.

Limitations

The study had a small sample size and was limited to previously untreated patients.

Participant Demographics

The median age of participants was 61 years, with 51 males and 18 females.

Statistical Information

P-Value

0.178

Confidence Interval

95% confidence interval 39-64%

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication